Cellular and molecular aspects of gastric cancer

References

• 1. Black RJ, Bray F, Ferlay J, Parkin DMCancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;33:1075–1107.[PubMed][Google Scholar]
• 2. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev. 1996;5:477–481.[PubMed]
• 3. Parkin DMGlobal cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543.[PubMed][Google Scholar]
• 4. Kuniyasu H, Yasui W, Yokozaki H, Tahara E. Helicobacter pylori infection and carcinogenesis of the stomach. Langenbecks Arch Surg. 2000;385:69–74.[PubMed]
• 5. LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965;64:31–49.[PubMed]
• 6. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.[PubMed]
• 7. Coussens LM, Werb ZInflammation and cancer. Nature. 2002;420:860–867.[Google Scholar]
• 8. WOOLF CM, ISAACSON EAAn analysis of 5 "stomach cancer families" in the state of Utah. Cancer. 1961;14:1005–1016.[PubMed][Google Scholar]
• 9. Marshall BJ, Warren JRUnidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315.[PubMed][Google Scholar]
• 10. Zarrilli R, Ricci V, Romano MMolecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage. Cell Microbiol. 1999;1:93–99.[PubMed][Google Scholar]
• 11. Everhart JERecent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am. 2000;29:559–578.[PubMed][Google Scholar]
• 12. Naito Y, Yoshikawa TMolecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress. Free Radic Biol Med. 2002;33:323–336.[PubMed][Google Scholar]
• 13. Segal ED, Lange C, Covacci A, Tompkins LS, Falkow SInduction of host signal transduction pathways by Helicobacter pylori. Proc Natl Acad Sci U S A. 1997;94:7595–7599.[Google Scholar]
• 14. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267–1271.[PubMed]
• 15. Suerbaum SGenetic variability within Helicobacter pylori. Int J Med Microbiol. 2000;290:175–181.[PubMed][Google Scholar]
• 16. Scott DR, Weeks D, Hong C, Postius S, Melchers K, Sachs GThe role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology. 1998;114:58–70.[PubMed][Google Scholar]
• 17. Weeks DL, Eskandari S, Scott DR, Sachs GA H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science. 2000;287:482–485.[PubMed][Google Scholar]
• 18. Eaton KA, Krakowka SEffect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect Immun. 1994;62:3604–3607.[Google Scholar]
• 19. Hansson LE, Nyrén O, Hsing AW, Bergström R, Josefsson S, Chow WH, Fraumeni JF Jr, Adami HOThe risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 1996;335:242–249.[PubMed][Google Scholar]
• 20. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.[PubMed]
• 21. Graham DY, Yamaoka YDisease-specific Helicobacter pylori virulence factors: the unfulfilled promise. Helicobacter. 2000;5 Suppl 1:S3–S9; discussion S27-S31.[PubMed][Google Scholar]
• 22. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, et al The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997;388:539–547.[PubMed][Google Scholar]
• 23. Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, et al Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 1999;397:176–180.[PubMed][Google Scholar]
• 24. Keates S, Keates AC, Warny M, Peek RM Jr, Murray PG, Kelly CPDifferential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag+ and cag- Helicobacter pylori. J Immunol. 1999;163:5552–5559.[PubMed][Google Scholar]
• 25. Suerbaum S, Josenhans C, Claus H, Frosch MBacterial genomics: seven years on. Trends Microbiol. 2002;10:351–353.[PubMed][Google Scholar]
• 26. Stein M, Rappuoli R, Covacci ATyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci U S A. 2000;97:1263–1268.[Google Scholar]
• 27. Glocker E, Lange C, Covacci A, Bereswill S, Kist M, Pahl HLProteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-kappaB activation. Infect Immun. 1998;66:2346–2348.[Google Scholar]
• 28. Parsonnet J, Friedman GD, Orentreich N, Vogelman HRisk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997;40:297–301.[Google Scholar]
• 29. Cover TL, Dooley CP, Blaser MJCharacterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun. 1990;58:603–610.[Google Scholar]
• 30. Peek RM Jr, Miller GG, Tham KT, Perez-Perez GI, Zhao X, Atherton JC, Blaser MJHeightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest. 1995;73:760–770.[PubMed][Google Scholar]
• 31. Peek RM Jr, Vaezi MF, Falk GW, Goldblum JR, Perez-Perez GI, Richter JE, Blaser MJRole of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. Int J Cancer. 1999;82:520–524.[PubMed][Google Scholar]
• 32. Kuck D, Kolmerer B, Iking-Konert C, Krammer PH, Stremmel W, Rudi JVacuolating cytotoxin of Helicobacter pylori induces apoptosis in the human gastric epithelial cell line AGS. Infect Immun. 2001;69:5080–5087.[Google Scholar]
• 33. Peek RM Jr. Helicobacter pylori strain-specific modulation of gastric mucosal cellular turnover: implications for carcinogenesis. J Gastroenterol. 2002;37 Suppl 13:10–16.[PubMed]
• 34. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Borén T. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science. 1998;279:373–377.[PubMed]
• 35. Peek RM Jr, Thompson SA, Donahue JP, Tham KT, Atherton JC, Blaser MJ, Miller GGAdherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome. Proc Assoc Am Physicians. 1998;110:531–544.[PubMed][Google Scholar]
• 36. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, et al Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002;94:1680–1687.[PubMed][Google Scholar]
• 37. El-Omar EM, Oien K, Murray LS, El-Nujumi A, Wirz A, Gillen D, Williams C, Fullarton G, McColl KEIncreased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H pylori. Gastroenterology. 2000;118:22–30.[PubMed][Google Scholar]
• 38. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, et al Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402.[PubMed][Google Scholar]
• 39. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, et al Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology. 2001;121:823–829.[PubMed][Google Scholar]
• 40. Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz CCytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut. 2004;53:1082–1089.[Google Scholar]
• 41. El-Omar EMThe importance of interleukin 1beta in Helicobacter pylori associated disease. Gut. 2001;48:743–747.[Google Scholar]
• 42. Genta RMThe immunobiology of Helicobacter pylori gastritis. Semin Gastrointest Dis. 1997;8:2–11.[PubMed][Google Scholar]
• 43. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, et al Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193–1201.[PubMed][Google Scholar]
• 44. Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara S, Shimosegawa TThe polymorphism interleukin 8 -251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut. 2005;54:330–335.[Google Scholar]
• 45. Savage SA, Abnet CC, Haque K, Mark SD, Qiao YL, Dong ZW, Dawsey SM, Taylor PR, Chanock SJPolymorphisms in interleukin -2, -6, and -10 are not associated with gastric cardia or esophageal cancer in a high-risk chinese population. Cancer Epidemiol Biomarkers Prev. 2004;13:1547–1549.[PubMed][Google Scholar]
• 46. Lu W, Pan K, Zhang L, Lin D, Miao X, You WGenetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population. Carcinogenesis. 2005;26:631–636.[PubMed][Google Scholar]
• 47. Cai L, Zheng ZL, Zhang ZFCytochrome p450 2E1 polymorphisms and the risk of gastric cardia cancer. World J Gastroenterol. 2005;11:1867–1871.[Google Scholar]
• 48. Magnusson PKE H, Eriksson I, Held M, Nyrén O, Engstrand L, Hansson LE, Gyllensten UBGastric cancer and human leukocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer Res. 2001;61:2684–2689.[PubMed][Google Scholar]
• 49. Mori N, Wada A, Hirayama T, Parks TP, Stratowa C, Yamamoto NActivation of intercellular adhesion molecule 1 expression by Helicobacter pylori is regulated by NF-kappaB in gastric epithelial cancer cells. Infect Immun. 2000;68:1806–1814.[Google Scholar]
• 50. Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology. 1997;113:1099–1109.[PubMed]
• 51. Maeda S, Yoshida H, Ogura K, Mitsuno Y, Hirata Y, Yamaji Y, Akanuma M, Shiratori Y, Omata M. H pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology. 2000;119:97–108.[PubMed]
• 52. Isomoto H, Mizuta Y, Miyazaki M, Takeshima F, Omagari K, Murase K, Nishiyama T, Inoue K, Murata I, Kohno SImplication of NF-kappaB in Helicobacter pylori-associated gastritis. Am J Gastroenterol. 2000;95:2768–2776.[PubMed][Google Scholar]
• 53. Sharma SA, Tummuru MK, Blaser MJ, Kerr LDActivation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-kappa B in gastric epithelial cells. J Immunol. 1998;160:2401–2407.[PubMed][Google Scholar]
• 54. Hatz RA, Rieder G, Stolte M, Bayerdörffer E, Meimarakis G, Schildberg FW, Enders GPattern of adhesion molecule expression on vascular endothelium in Helicobacter pylori-associated antral gastritis. Gastroenterology. 1997;112:1908–1919.[PubMed][Google Scholar]
• 55. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DAToll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185–192.[PubMed][Google Scholar]
• 56. Medzhitov R, Preston-Hurlburt P, Janeway CA JrA human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397.[PubMed][Google Scholar]
• 57. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira SCutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749–3752.[PubMed][Google Scholar]
• 58. Kawai T, Adachi O, Ogawa T, Takeda K, Akira SUnresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999;11:115–122.[PubMed][Google Scholar]
• 59. Kawai T, Takeuchi O, Fujita T, Inoue J, Mühlradt PF, Sato S, Hoshino K, Akira SLipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 2001;167:5887–5894.[PubMed][Google Scholar]
• 60. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H, Murphy M, Liao F, Farber J, Cassatella MAGene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol. 1999;162:4928–4937.[PubMed][Google Scholar]
• 61. Bogdan CNitric oxide and the immune response. Nat Immunol. 2001;2:907–916.[PubMed][Google Scholar]
• 62. Alderton WK, Cooper CE, Knowles RGNitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357:593–615.[Google Scholar]
• 63. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M, Noonan DM, Albini ANeutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J. 2002;16:267–269.[PubMed][Google Scholar]
• 64. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara SCutting edge: impaired Toll-like receptor expression and function in aging. J Immunol. 2002;169:4697–4701.[PubMed][Google Scholar]
• 65. Mannick EE, Bravo LE, Zarama G, Realpe JL, Zhang XJ, Ruiz B, Fontham ET, Mera R, Miller MJ, Correa PInducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res. 1996;56:3238–3243.[PubMed][Google Scholar]
• 66. Jaiswal M, LaRusso NF, Gores GJNitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G626–G634.[PubMed][Google Scholar]
• 67. Salvemini D, Seibert K, Masferrer JL, Settle SL, Misko TP, Currie MG, Needleman PNitric oxide and the cyclooxygenase pathway. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:491–493.[PubMed][Google Scholar]
• 68. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman PNitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A. 1993;90:7240–7244.[Google Scholar]
• 69. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Nakama A, Takei Y, Nagano K, Matsui H, Kawano S, Hori MExpression of the cyclooxygenase-2 gene in gastric epithelium. J Clin Gastroenterol. 1997;25 Suppl 1:S105–S110.[PubMed][Google Scholar]
• 70. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen MExpression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280.[PubMed][Google Scholar]
• 71. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FKCyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 2000;157:729–735.[Google Scholar]
• 72. Turini ME, DuBois RNCyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002;53:35–57.[PubMed][Google Scholar]
• 73. Smith WL, Garavito RM, DeWitt DLProstaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157–33160.[PubMed][Google Scholar]
• 74. Williams CS, Smalley W, DuBois RNAspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest. 1997;100:1325–1329.[Google Scholar]
• 75. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PECyclooxygenase in biology and disease. FASEB J. 1998;12:1063–1073.[PubMed][Google Scholar]
• 76. Tsujii M, Kawano S, DuBois RNCyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336–3340.[Google Scholar]
• 77. Tsujii M, DuBois RNAlterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501.[PubMed][Google Scholar]
• 78. Davies GR, Simmonds NJ, Stevens TR, Sheaff MT, Banatvala N, Laurenson IF, Blake DR, Rampton DS. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut. 1994;35:179–185.
• 79. Suzuki H, Miura S, Imaeda H, Suzuki M, Han JY, Mori M, Fukumura D, Tsuchiya M, Ishii HEnhanced levels of chemiluminescence and platelet activating factor in urease-positive gastric ulcers. Free Radic Biol Med. 1996;20:449–454.[PubMed][Google Scholar]
• 80. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara EFrequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992;189:227–232.[PubMed][Google Scholar]
• 81. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y, Tahara EAberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer. 1993;55:72–75.[PubMed][Google Scholar]
• 82. Katoh M, Hattori Y, Sasaki H, Tanaka M, Sugano K, Yazaki Y, Sugimura T, Terada MK-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase. Proc Natl Acad Sci U S A. 1992;89:2960–2964.[Google Scholar]
• 83. Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H, Katoh O, Yoshida T, Sugimura T, Terada MK-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci U S A. 1990;87:5983–5987.[Google Scholar]
• 84. Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M, Sugimura TGenetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988;2:283–287.[PubMed][Google Scholar]
• 85. Oda N, Tsujino T, Tsuda T, Yoshida K, Nakayama H, Yasui W, Tahara EDNA ploidy pattern and amplification of ERBB and ERBB2 genes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;58:273–277.[PubMed][Google Scholar]
• 86. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki I, Endou Y. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer. 1991;67:2914–2918.[PubMed]
• 87. Lee KH, Lee JS, Suh C, Kim SW, Kim SB, Lee JH, Lee MS, Park MY, Sun HS, Kim SH. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer. 1995;75:2794–2801.[PubMed]
• 88. Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, Nakamura Y, Kajiyama G, Tahara EFrequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res. 1991;51:2926–2931.[PubMed][Google Scholar]
• 89. Isogaki J, Shinmura K, Yin W, Arai T, Koda K, Kimura T, Kino I, Sugimura HMicrosatellite instability and K-ras mutations in gastric adenomas, with reference to associated gastric cancers. Cancer Detect Prev. 1999;23:204–214.[PubMed][Google Scholar]
• 90. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi SDetection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res. 1991;51:3056–3058.[PubMed][Google Scholar]
• 91. Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H, Tahara Ep53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol. 1992;119:67–70.[PubMed][Google Scholar]
• 92. Tohdo H, Yokozaki H, Haruma K, Kajiyama G, Tahara Ep53 gene mutations in gastric adenomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;63:191–195.[PubMed][Google Scholar]
• 93. Sakurai S, Sano T, Nakajima TClinicopathological and molecular biological studies of gastric adenomas with special reference to p53 abnormality. Pathol Int. 1995;45:51–57.[PubMed][Google Scholar]
• 94. Ochiai A, Yamauchi Y, Hirohashi Sp53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer. 1996;69:28–33.[PubMed][Google Scholar]
• 95. Sugimura T, Fujimura S, Baba TTumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 1970;30:455–465.[PubMed][Google Scholar]
• 96. Mirvish SSKinetics of nitrosamide formation from alkylureas, N-alkylurethans, and alkylguanidines: possible implications for the etiology of human gastric cancer. J Natl Cancer Inst. 1971;46:1183–1193.[PubMed][Google Scholar]
• 97. Pérez-Pérez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina-Menchaca R, Garza-González ERole of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol. 2005;40:56–60.[PubMed][Google Scholar]
• 98. Yokozaki H, Shitara Y, Fujimoto J, Hiyama T, Yasui W, Tahara EAlterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer. 1999;83:192–196.[PubMed][Google Scholar]
• 99. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon PCloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 1982;10:7895–7903.[Google Scholar]
• 100. Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MCGastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996;274:259–262.[PubMed][Google Scholar]
• 101. Tahara EGenetic pathways of two types of gastric cancer. IARC Sci Publ. 2004:327–349.[PubMed][Google Scholar]
• 102. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie DIdentification of FAP locus genes from chromosome 5q21. Science. 1991;253:661–665.[PubMed][Google Scholar]
• 103. Nakatsuru S, Yanagisawa A, Furukawa Y, Ichii S, Kato Y, Nakamura Y, Horii ASomatic mutations of the APC gene in precancerous lesion of the stomach. Hum Mol Genet. 1993;2:1463–1465.[PubMed][Google Scholar]
• 104. Nakatsuru S, Yanagisawa A, Ichii S, Tahara E, Kato Y, Nakamura Y, Horii ASomatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum Mol Genet. 1992;1:559–563.[PubMed][Google Scholar]
• 105. Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R, Yasui W, Tahara EInactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation. 2001;68:13–21.[PubMed][Google Scholar]
• 106. Ayhan A, Yasui W, Yokozaki H, Seto M, Ueda R, Tahara ELoss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res. 1994;85:584–591.[Google Scholar]
• 107. Ito YOncogenic potential of the RUNX gene family: 'overview'. Oncogene. 2004;23:4198–4208.[PubMed][Google Scholar]
• 108. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GHMethylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004;84:479–484.[PubMed][Google Scholar]
• 109. Sakakura C, Hagiwara A, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Ito K, Yamagishi H, Yazumi S, et al Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer. Int J Cancer. 2005;113:221–228.[PubMed][Google Scholar]
• 110. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue Ki, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113–124.[PubMed][Google Scholar]
• 111. Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate RAnalysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosomes Cancer. 1997;20:98–102.[PubMed][Google Scholar]
• 112. Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, Kim HY, Lee YS, Kang GH, Jeoung DIPromoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun. 2003;307:52–63.[PubMed][Google Scholar]
• 113. Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, Matsusaki K, Ishikawa T, Tahara E, Yasui WAcetylated histone H4 is reduced in human gastric adenomas and carcinomas. J Exp Clin Cancer Res. 2002;21:377–382.[PubMed][Google Scholar]
• 114. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Höfler HE-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54:3845–3852.[PubMed][Google Scholar]
• 115. Wijnhoven BP, Dinjens WN, Pignatelli ME-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg. 2000;87:992–1005.[PubMed][Google Scholar]
• 116. Smith ME, Pignatelli MThe molecular histology of neoplasia: the role of the cadherin/catenin complex. Histopathology. 1997;31:107–111.[PubMed][Google Scholar]
• 117. Tucker EL, Pignatelli MCatenins and their associated proteins in colorectal cancer. Histol Histopathol. 2000;15:251–260.[PubMed][Google Scholar]
• 118. Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, Birchmeier W, Höfler H, et al Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene. 1999;18:4301–4312.[PubMed][Google Scholar]
• 119. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe N, Niitsu YLoss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol. 1995;15:1175–1181.[Google Scholar]
• 120. Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A, Rimm DL, Costa J, Fearon ERBeta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ. 1999;10:369–376.[PubMed][Google Scholar]
• 121. Shibata T, Ochiai A, Kanai Y, Akimoto S, Gotoh M, Yasui N, Machinami R, Hirohashi SDominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene. 1996;13:883–889.[PubMed][Google Scholar]
• 122. Yokozaki H, Ito R, Nakayama H, Kuniyasu H, Taniyama K, Tahara EExpression of CD44 abnormal transcripts in human gastric carcinomas. Cancer Lett. 1994;83:229–234.[PubMed][Google Scholar]
• 123. Higashikawa K, Yokozaki H, Ue T, Taniyama K, Ishikawa T, Tarin D, Tahara EEvaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer. 1996;66:11–17.[PubMed][Google Scholar]
• 124. Yoshida K, Bolodeoku J, Sugino T, Goodison S, Matsumura Y, Warren BF, Toge T, Tahara E, Tarin DAbnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res. 1995;55:4273–4277.[PubMed][Google Scholar]
• 125. Weber GF, Ashkar S, Glimcher MJ, Cantor HReceptor-ligand interaction between CD44 and osteopontin (Eta-1) Science. 1996;271:509–512.[PubMed][Google Scholar]
• 126. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara ECo-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79:127–132.[PubMed][Google Scholar]
• 127. Nakayama H, Yasui W, Yokozaki H, Tahara EReduced expression of nm23 is associated with metastasis of human gastric carcinomas. Jpn J Cancer Res. 1993;84:184–190.[Google Scholar]
• 128. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara EExpression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer. 1994;56:474–480.[PubMed][Google Scholar]
• 129. Akama Y, Yasui W, Yokozaki H, Kuniyasu H, Kitahara K, Ishikawa T, Tahara EFrequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res. 1995;86:617–621.[Google Scholar]
• 130. Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara EReduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 1997;88:625–629.[Google Scholar]
• 131. Yasui W, Naka K, Suzuki T, Fujimoto J, Hayashi K, Matsutani N, Yokozaki H, Tahara EExpression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma. Oncol Rep. 1999;6:983–987.[PubMed][Google Scholar]
• 132. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara EExpression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999;81:535–538.[PubMed][Google Scholar]
• 133. Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, Moslein G, Baker SM, Liskay RM, Burgart LJ, et al Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996;56:4836–4840.[PubMed][Google Scholar]
• 134. Keller G, Grimm V, Vogelsang H, Bischoff P, Mueller J, Siewert JR, Höfler HAnalysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. Int J Cancer. 1996;68:571–576.[PubMed][Google Scholar]
• 135. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, et al Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999;59:1090–1095.[PubMed][Google Scholar]
• 136. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JChMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res. 1999;59:159–164.[PubMed][Google Scholar]
• 137. Hamamoto T, Yokozaki H, Semba S, Yasui W, Yunotani S, Miyazaki K, Tahara EAltered microsatellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers. J Clin Pathol. 1997;50:841–846.[Google Scholar]
• 138. Semba S, Yokozaki H, Yasui W, Tahara EFrequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer. Int J Oncol. 1998;12:1245–1251.[PubMed][Google Scholar]
• 139. Yasui W, Tahara H, Tahara E, Fujimoto J, Nakayama J, Ishikawa F, Ide T, Tahara EExpression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas. Jpn J Cancer Res. 1998;89:1099–1103.[Google Scholar]
• 140. Yasui W, Tahara E, Tahara H, Fujimoto J, Naka K, Nakayama J, Ishikawa F, Ide T, Tahara EImmunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Jpn J Cancer Res. 1999;90:589–595.[Google Scholar]
• 141. Yasui W, Hata J, Yokozaki H, Nakatani H, Ochiai A, Ito H, Tahara EInteraction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer. 1988;41:211–217.[PubMed][Google Scholar]
• 142. Yoshida K, Tsujino T, Yasui W, Kameda T, Sano T, Nakayama H, Toge T, Tahara EInduction of growth factor-receptor and metalloproteinase genes by epidermal growth factor and/or transforming growth factor-alpha in human gastric carcinoma cell line MKN-28. Jpn J Cancer Res. 1990;81:793–798.[Google Scholar]
• 143. Kuniyasu H, Yoshida K, Yokozaki H, Yasui W, Ito H, Toge T, Ciardiello F, Persico MG, Saeki T, Salomon DSExpression of cripto, a novel gene of the epidermal growth factor family, in human gastrointestinal carcinomas. Jpn J Cancer Res. 1991;82:969–973.[Google Scholar]
• 144. Akagi M, Kawaguchi M, Liu W, McCarty MF, Takeda A, Fan F, Stoeltzing O, Parikh AA, Jung YD, Bucana CD, et al Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer. 2003;88:796–802.[Google Scholar]
• 145. Ito R, Kitadai Y, Kyo E, Yokozaki H, Yasui W, Yamashita U, Nikai H, Tahara EInterleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res. 1993;53:4102–4106.[PubMed][Google Scholar]
• 146. Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, Yamamoto S, Sumii K, Kajiyama G, Fidler IJ, et al Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res. 2000;6:2735–2740.[PubMed][Google Scholar]
• 147. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ, et al Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol. 1998;152:93–100.[Google Scholar]
• 148. Yoshida K, Yokozaki H, Niimoto M, Ito H, Ito M, Tahara EExpression of TGF-beta and procollagen type I and type III in human gastric carcinomas. Int J Cancer. 1989;44:394–398.[PubMed][Google Scholar]
• 149. Yamamoto S, Yasui W, Kitadai Y, Yokozaki H, Haruma K, Kajiyama G, Tahara EExpression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int. 1998;48:499–506.[PubMed][Google Scholar]
• 150. Tanimoto H, Yoshida K, Yokozaki H, Yasui W, Nakayama H, Ito H, Ohama K, Tahara EExpression of basic fibroblast growth factor in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;61:263–267.[PubMed][Google Scholar]